register free | resend password


Themenbereich / / Biotech

Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

Arch Biopartners Initiates Manufacturing Process for Metablok

TORONTO, ONTARIO -- (Marketwired) -- 10/10/17 -- Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) a portfolio-based biotechnology company, today announced it has engaged CSBio in Menlo Park, California, to begin the manufacturing process for Metablok, the Company''s drug candidate for treating inflammation, cancer metastasis and sepsis.Arch is planning a Phase I human trial to evaluate Metablok''s safety and pharmacokinetic profile. The phase I study will be followed by Phase II clinical trials to evaluate the efficacy of Metablok in prevent ...


ANGLE plc Announces Circulating Tumour Cells, Harvested From Blood, Grown in the Laboratory for the First Time

GUILDFORD, SURREY -- (Marketwired) -- 10/09/17 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY),AIM: AGL; OTCQX: ANPCYHeinrich Heine University researchers demonstrate that CTCs harvested with Parsortix™ from leukapheresis blood product can be culturedCultured cells continue to proliferate several months after Parsortix™ harvestANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, today announces that one of its customers has successfully grown circulating tumor cells (CTCs) harvested by Parsortix™ in the laboratory. This is the first time the ability to culture CTCs harvested from ...


ANGLE plc Announces Parsortix(TM) System Central to Potential New Analytical Protocol for Identifying Drugs That May Arrest Metastasis

GUILDFORD, SURREY -- (Marketwired) -- 10/09/17 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY)AIM: AGL; OTCQX: ANPCYReal time technique being developed to assess the impact of cancer drugs on living circulating tumour cells harvested from patient blood using Parsortix™ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, today announces that Professor Stuart Martin from the University of Maryland School of Medicine, USA, presented new breakthrough research using ANGLE''s Parsortix™ system at Europe''s leading circulating tumour cell (CTC) conference, the Third ...


Angle''s Parsortix(TM) System Showcased in Multiple Presentations at Leading European Circulating Tumour Cell Conference

GUILDFORD, UNITED KINGDOM -- (Marketwired) -- 10/09/17 -- Angle PLC (OTCQX: ANPCY) (AIM: AGL)AIM: AGL; OTCQX: ANPCYTraction of Company''s CTC harvesting system accelerating as customers and key opinion leaders feature Parsortix™ in 8 posters and five plenary presentationsWell positioned to become default cancer liquid biopsy systemANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, today announces that its Parsortix™ system was widely showcased by the Company''s customers and Key Opinion Leaders in the field of circulating tumour cells (CTCs) in pres ...


Theratechnologies Announces Financial Results for Third Quarter of 2017

MONTREAL, QUEBEC -- (Marketwired) -- 10/05/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2017.Third quarter 2017 financial highlights"With three quarters into our fiscal year, our business plan is very much on track. Sales of EGRIFTA® are growing and the ibalizumab file is progressing as we anticipated. In fact, we are even ahead of our plan for ibalizumab in Europe as we started investing in regulatory work much sooner than we expected," said Luc Tanguay, President and Chief Executive Officer ...


Angle PLC: Results of Fundraising

GUILDFORD, SURREY -- (Marketwired) -- 10/05/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)(AIM:AGL OTCQX:ANPCY)ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading player in the liquid biopsy market, is pleased to announce that, further to the announcement made earlier today, the Company has successfully raised a total of approximately £ 12.2 million (before expenses) with new and existing investors consisting of 3,757,146 EIS/VCT Placing Shares, 25,680,006 General Placing Shares, 772,857 General Subscription Shares and 4,579,169 Covington Subscription Shares, all at a price of 35 pence per New Ordinary Sha ...


Angle PLC: Angle PLC Announces Proposed Placing of 29,437,152 New Ordinary Shares at 35 pence per share Proposed subscriptions of 5,352,026 New Ordinary Shares at 35 pence per share Conditional Acquisition of certain assets of Axela Inc.

GUILDFORD, SURREY -- (Marketwired) -- 10/05/17 -- Angle PLC (OTCQX: ANPCY) (AIM: AGL)(AIM: AGL; OTCQX: ANPCY)ANGLE plc (AIM: AGL; OTCQX: ANPCY), a leading player in the liquid biopsy market, today announces the conditional acquisition of certain assets of Axela Inc. ("") for a total consideration payable, subject to certain balancing adjustments, of CAD6.15 million (approximately £ 3.7 million) (the ""), together with a conditional Placing and subscriptions (including a subscription by Covington, Axela''s major shareholder and creditor) to raise in aggregate appr ...


Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017(TM)

MONTREAL, QUEBEC -- (Marketwired) -- 10/04/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced 48-week efficacy and safety results for ibalizumab in patients infected with multidrug resistant HIV-1 who completed the 24-week Phase III study (TMB-301) and continued treatment in the Expanded Access Program study (TMB-311). These data are being presented in an oral presentation at IDWeek 2017™ in San Diego (abstract #1686).Of the 27 patients who completed the 24-week treatment period of TMB-301 in the U.S., all entered TMB-311, where patients continued to receive ibalizuma ...


Synthego and Thermo Fisher Scientific Align to Manufacture and Distribute Synthetic Guide RNA Products for CRISPR Genome Engineering

REDWOOD CITY, CA -- (Marketwired) -- 10/04/17 -- , a leading provider of genome engineering solutions, announces a new alignment with Thermo Fisher Scientific to manufacture and distribute world-class quality synthetic guide RNA products. Synthego''s synthetic guide RNA portfolio and industry-leading synthetic guide RNA manufacturing capabilities will be utilized to produce synthetic guide RNAs under Thermo Fisher''s Invitrogen TrueGuide brand that will be marketed and sold across Thermo Fisher channels worldwide.In use by leading commercial and academic institutions in ov ...


Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results

LONDON, ONTARIO and BOSTON, MASSACHUSETTS -- (Marketwired) -- 09/29/17 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three-month period ended July 31, 2017. Recent highlights include:Progressed the Phase 1 clinical trial of COTI-2:Secured additional funding:Broadened the leadership team:"We made considerable progress in our Phase 1 trial of COTI-2 this quarter, and were pleased to report preliminary clinical data, suggesting the drug is generally safe and well ...


Arch Biopartners'' GMP Manufacturing of AB569 Progresses to Final Production Stage

TORONTO, ONTARIO -- (Marketwired) -- 09/28/17 -- Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) today announced that the good manufacturing practice (GMP) production campaign for AB569 has advanced to the GMP glass vial filling stage. AB569 is the Company''s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients as well as many other indications.AB569 is a potential stand alone or complementary treatment to existing and emerging st ...


Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis

TORONTO, ONTARIO -- (Marketwired) -- 09/27/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (OTCQB: RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has submitted an application to the U.S. Food and Drug Administration ("FDA") seeking orphan drug designation of cannabidiol ("CBD") for the treatment of autoimmune hepatitis ("AIH"), a rare liver disease."This orphan drug designation application is an imp ...


Chemistree Upgrades U.S. Trading to OTCQB

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/26/17 -- Chemistree Technology Inc. (CSE: CHM) (CSE: CHM.CN) (CNSX: CHM) (OTCQB: CHMJF) (the "Company") is pleased to announce that Chemistree''s common shares have been approved for trading on the OTCQB Venture Market in the United States under the new trading symbol CHMJF, effective September 26, 2017.Listing on the OTCQB is part of Chemistree''s overall strategy to increase its potential audience of international investors. It will provide the company with a significant trading platform for its current shareh ...


Realm Therapeutics Announces $26 Million PIPE Financing

MALVERN, PA -- (Marketwired) -- 09/21/17 -- (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce today that it has successfully secured funding commitments to raise gross proceeds of $26 million through a private placement in the United States and the United Kingdom (the "PIPE") to existing and new investors, including healthcare specialist funds OrbiMed, BVF Partners LP, RA Capital Management, Abingworth BioEquities Master Fund Ltd and Polar Capital. The PIPE is conditional upon approval of ...


Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board

REDWOOD CITY, CA -- (Marketwired) -- 09/20/17 -- , a leading provider of genome engineering solutions, announces the appointment of Sir Andrew Witty, former CEO of GlaxoSmithKline (GSK) and Director at UnitedHealth Group, to the Synthego advisory board."Synthego''s vision for automating biological research will revolutionize the industry by accelerating application development and enabling machine learning based insights. Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach,&qu ...


Treos Bio Enters into Agreement with PPD to Manage First-in-Man Trial of Its Lead Therapeutic Cancer Vaccine Program

SAN FRANCISCO, CA and LONDON, UNITED KINGDOM -- (Marketwired) -- 09/20/17 -- , which is developing precision peptide cancer vaccines coupled with companion diagnostics, today announced it has entered into an agreement with Pharmaceutical Product Development, LLC (), a leading global contract research organization. As part of the agreement, , a PPD service dedicated to biotech and small to mid-sized pharmaceutical companies, will manage Treos Bio''s first-in-man study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. This study will be conducted in the United S ...


Acquisition and Disposition of Securities of Hemostemix Inc.

CALGARY, ALBERTA -- (Marketwired) -- 09/19/17 -- Wood Capital Ltd. ("Wood Capital") an entity controlled by Blake Wood, acquired 88,000,000 units ("Units") of Hemostemix Inc. (the "Issuer") (TSX VENTURE: HEM), with each Unit consisting of one common share (a "Share") of the Issuer and one-half Share purchase warrant (a "Warrant"), with each whole Warrant entitling the holder to acquire one additional Share for CDN$0.20 for a period of 2 years from the issuance of the Warrants, with an accelerated exercise provision attached to each Warrant co ...


Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases

TORONTO, ONTARIO -- (Marketwired) -- 09/19/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation ("SCRF"), under which Revive will acquire an exclusive license from SCRF to develop and commercialize a portfolio of patents based on cannabinoid-based therapeutics, such as Cannabidiol, in the treatment o ...


Ibalizumab Long-Term Safety and Efficacy Data to be Presented at IDWeek 2017 in San Diego

MONTREAL, QUEBEC -- (Marketwired) -- 09/18/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that the abstract entitled "48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1" will be featured in an oral presentation at the IDWeek Conference to be held in San Diego, CA, from October 4 to 8, 2017. Dr. Brinda Emu, Assistant Professor of Medicine, Infectious Diseases, Yale School of Medicine, New Haven, CT will be presenting detailed data related to the long-term efficacy and safety of ibalizumab, an invest ...


Angle PLC: Holding(s) in Company

GUILDFORD, UNITED KINGDOM -- (Marketwired) -- 09/13/17 -- (AIM: AGL) (OTCQX: ANPCY) ...


Page 4 from 247:  « ..  3 4 5  6  .. » 247

All members: 9 352
Register today: 3
Register yesterday: 2
Members online: 0
Guests online: 54

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.